Lucentis

Mar 18, 2026

Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy and primarily affects people over 65, making aging a key driver of disease burden and of the growing retinal vascular occlusion market. RVO is broadly classified into central retinal vein occlusion (CRVO) and branch...

Sep 15, 2025

Neovascular age-related macular degeneration (nAMD or Wet AMD) is a progressive retinal condition and a primary cause of central vision loss among individuals over 60 years old. While it represents only 10–15% of overall AMD cases, it is responsible for nearly 90% of severe vision impairment linked to the disease. ...

Jul 22, 2022

Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landscape changed the market once dominated by Roche.Moving forward, RVO’s robust pipeline, along with several VEGF inhibitors, creates trouble for the big ones; Lucentis and Eylea. Retinal vein occlusion is the second most common s...

Mar 30, 2022

Patent protection and expiration is one of the hot topics in the healthcare industry. Patent protection results in high sales and profits for the initial developers and innovators of the drugs, and as per various estimates, the gross profit margins for the Patent protected drugs exceed 90% in some cases. However, t...

Apr 04, 2019

AgomAb Therapeutics raises USD 23.5 million for its agomAbs A Belgian biotherapeutics company AgomAb Therapeutics which has been in a long run of making agonistic antibodies has secured USD 23.5 million in a Series A financing round from international investor syndicate co-led by V-Bio Ventures (Belgium) and Adv...

Oct 16, 2017

Wet AMD is a chronic eye disease that causes blurred vision or a blind spot in a person’s visual field. It is characterized by abnormal blood vessels that leak blood and fluids into the macula, a region of the eye that is responsible for sharp, central vision. Age-related macular degeneration (AMD) is a common eye c...